PCI Biotech Holding ASA: PCI Biotech interim first-half year 2022 results

Oslo (Norway), 31 August 2022 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, today announces its interim first-half year 2022 results. Please find enclosed the report and presentation. Highlights Corporate*The

Related Keywords

Germany ,Norway ,United States ,Denmark ,Munich ,Bayern ,United Kingdom ,Zurich ,Züsz ,Switzerland ,Sweden ,Oslo ,Norwegian ,Ronny Skuggedal ,Ludovic Robin ,Ernst Wagner ,Amir Snapir ,Hans Peter ,Scientific Advisory Committee ,Biotech Holding ,University Of Zurich ,Research Council Of Norway ,Research Council ,Per Walday ,Holding Half Yearly ,Norwegian Securities Trading ,Biotech ,Molding ,Interim ,First ,Calf ,Ear ,022 ,Results ,